Tradestie Institutional Equity Comparison Engine

DMAC vs FENC โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

FENC Overall Edge

FENC Captures Institutional Edge (4โ€“0 Pillars ยท 8โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Fennec Pharmaceuticals Inc. Common Stock (FENC) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, DMAC trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus FENC at 11.2x Forward P/E and 5.6% operating margin (+57.3% YoY). In options structure, DMAC sits in SURGE (14th %ile IV; Dealer Gamma Walls on Pro) against FENC sits in BREAKOUT (24th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner FENC
DMAC N/M vs FENC 11.2x Fwd P/E
Growth & Margin Winner FENC
Op Margin 0.0% vs 5.6% ยท YoY +0.0% vs +57.3%
Momentum & Technical Winner FENC
1Y +55.3% vs +56.0% ยท 52W Pos 55% vs 84%
Options & Structure Winner FENC
SURGE (14th %ile IV) vs BREAKOUT (24th %ile IV)
DMAC NASDAQ
DiaMedica Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$8.41
-4.27% 1D
Market Cap $503.1M
1M Return +11.16%
1Y Return +55.26%
Forward P/E N/M
Unified AI Score
46.3 / 100 HOLD
Tech 30.0 Fund 51.0 Flow 65.0 Mom 60.0
FENC NASDAQ
Fennec Pharmaceuticals Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$12.00
+3.27% 1D
Market Cap $405.7M
1M Return +20.24%
1Y Return +56.05%
Forward P/E 11.2x
Unified AI Score
44.2 / 100 HOLD
Tech 15.0 Fund 49.0 Flow 74.0 Mom 74.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: DMAC +55.26% FENC +56.05% Spread: +0.79 pp (FENC Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period DMAC Revenue FENC Revenue DMAC Op. Margin FENC Op. Margin Margin Edge
FY2018 $0M N/A -1352.2% N/A DMAC
FY2020 N/A $0M N/A -10520.6% FENC
FY2022 N/A $0M N/A -1471.6% FENC
FY2023 N/A $20M N/A -60.1% FENC
FY2024 N/A $50M N/A 5.4% FENC
FY2025 N/A $40M N/A -14.1% FENC

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: DMAC (2) vs FENC (8)
Institutional Metric DMAC FENC Criterion Row Winner
Market Capitalization Scale $503.1M $405.7M Larger Scale DMAC
Trailing P/E Ratio Valuation N/M 12.6x Lower Multiple FENC
Forward P/E Ratio Valuation N/M 11.2x Lower Multiple FENC
Revenue Growth (YoY) Growth +0.0% +57.3% Higher Growth FENC
Operating Margin (TTM) Profitability 0.0% 5.6% Higher Margin FENC
Net Profit Margin Profitability 0.0% 3.0% Higher Margin FENC
Return on Equity (ROE) Capital Efficiency -114.6% 9.1% Higher ROE FENC
52-Week Range Position Momentum 55% ($5โ€“$11) 84% ($6โ€“$13) Stronger Trend FENC
Beta / 30D Volatility Risk Regime 1.74ฮฒ ยท 98% Vol 1.71ฮฒ ยท 69% Vol Lower Realized Risk FENC
Unified Institutional Score Composite Signal 46.3 / 100 (HOLD) 44.2 / 100 (HOLD) Higher Composite DMAC

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full DMAC vs FENC Buy Guide
DMAC SURGE
8d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 14th %ile
IV Regime Compressed (<25th %ile)
Live DMAC Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
FENC BREAKOUT
98d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 24th %ile
IV Regime Compressed (<25th %ile)
Live FENC Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither DMAC nor FENC registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.